ABBV Jan 2025 80.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 11:19AM EDT. Market open.
| Previous Close | 84.01 |
| Open | 84.25 |
| Bid | 93.10 |
| Ask | 96.75 |
| Strike | 80.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 84.01 - 84.25 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksAbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.
Investor's Business DailyThe Bad News Heading Into AbbVie's First-Quarter Earnings Report
AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
ZacksEarnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
© 2024 Yahoo. All rights reserved.